Discover Great Companies Discover Great Clients
Popularity  25.9万   |   Followers  392   |   Likes  75   |   Feedback  265 Claim this company

An internationally leading modern pharmaceutical flagship enterprise

No.18 Zhuhai Popularity Ranking No.14 Xiangzhou District No.477 Guangdong No.1 Guo Chan Chemical No.1 Sheng Wu Ke Ji / Biotechnology Engineering No.1 Biopharmaceuticals No.1 Biotechnology Pharmaceuticals No.1 Zhong Pharmaceuticals No.1 Reagents No.1 Pharmaceutical Technology No.1 Biological Products No.1 Pharmaceutical R&D No.1 Lin Chuang Yi Xue No.2 Raw Materials No.2 Health 驰名商标 国家技术创新示范企业 省部级科技进步奖 国药准字 国家科技进步奖 省级高新技术企业
More

Company Overview

  • Nature: Listed Company Size: More than 10,000 emp Founded: 41年
  • Industry: Pharmaceuticals/Biotechnology
  • Full name: Livzon Pharmaceutical Group Inc.。

Development Stage

  • Stage: IPO上市, 主板, 深交所。
  • Ranking: Ranked #18 in Zhuhai by popularity Ranked #1 in Zhuhai Guo Chan Chemical Company by popularity Ranked #1 in Zhuhai Sheng Wu Ke Ji / Biotechnology Engineering Company by popularity Ranked #1 in Zhuhai Biopharmaceuticals Company by popularity Ranked #1 in Zhuhai Biotechnology Pharmaceuticals Company by popularity
  • Honors: 2025中国新经济500强 2025中国石油和化工500强 驰名商标 国家技术创新示范企业 According to algorithm
  • News: 2025-05-22:丽珠集团:子公司拟15.87亿元收购越南IMP公司64.81%股份。
  • Salary: 46.9% of positions earn 10-20K, In 2026 vs last yeargrew by 9%.。Master's salary: ¥27.3K, Doctorate salary: ¥40.0K.
  • R&D: "Medical & Health/Beauty & Healthcare" demand: 26.5%, "Computer/Network/Technology": 10.2%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 9.3%。
  • Recruiting: In 2026 vs 2025grew by 33%. Demand for highly educated talent: Master's: 35, Doctorate: 2.
  • Requirement: Education: 本科 leads with 55.4%. Experience: 1-3年 leads with 36.1%.
  • Region: Distributed across 32 regions, 深圳: 14.1%, 珠海: 11.5%, 成都: 5.8%, 北京: 4.8%.

About the Company

[Summary] An internationally leading modern pharmaceutical flagship enterprise

Livzon Pharmaceutical (A-share code: 000513.SZ; H-share code: 01513.HK) is a large comprehensive pharmaceutical group covering pharmaceutical R&D, production, and commercialization. It is also a pharmaceutical listed company dual-listed on the Shenzhen Stock Exchange and the Hong Kong Stock Exchange. Its products broadly cover chemical drugs, biological drugs, and traditional Chinese medicine. In the fiscal year 2025, the company achieved an operating revenue of RMB 12.020 billion and a net profit of RMB 2.009 billion.


To continuously enhance innovation capabilities and accelerate transformation and upgrading, Livzon Pharmaceutical has been increasing R&D investment. It has successively established the "National Recognized Enterprise Technology Center," "National and Local Joint Engineering Center for Long-acting Microspheres," "National Engineering Technology Research Center for Modernization of Traditional Chinese Medicine," and "Livzon Group Postdoctoral Research Workstation," building a competitive R&D innovation system.


In the field of chemical drugs, Livzon Pharmaceutical pioneered the development of Yilian® (Ilaprazole), China's first 1.1-class innovative drug in the digestive field, ushering in the era of innovative PPI acid-suppression therapy in China. The company focuses on the development of innovative drugs, high-barrier complex formulations, and products with high clinical value, laying out its portfolio around digestive, mental/neurological, assisted reproduction, anti-infection, and chronic diseases such as autoimmune, metabolic, and cardiovascular/cerebrovascular fields, thereby building a product matrix with international competitiveness. In recent years, the company has established a pipeline covering multiple Class 1 innovative drugs through self-research and BD, and has positioned products with "first-in-class" or "best-in-class" potential. Meanwhile, as a leading microsphere formulation enterprise in China, Livzon has built the National and Local Joint Engineering Center for Long-acting Microsphere Technology. After ten years of arduous R&D, it has successively launched improved new drugs Weibaoning® and Aliwei®.


In the field of biological drugs, the company focuses on autoimmune diseases, infectious disease prevention, and assisted reproduction, concentrating on novel molecules, novel targets, and differentiated molecular design. It has multiple biological new drug projects under development and has established four platforms: "early drug discovery, druggability assessment, integrated upstream and downstream R&D and quality evaluation of macromolecular protein drugs, and innovative vaccine technology." It has also built commercial production bases for recombinant protein drugs and vaccines, covering the entire biological drug R&D process.


In the field of traditional Chinese medicine (TCM), as a pioneer in the modernization transformation of Chinese medicine, Livzon continuously deepens its practices in TCM innovation and industrialization. It has formed a three-dimensional product matrix covering innovative TCM, classic famous formulas, and health products. It has launched over twenty exclusive TCM products, including Shenqi Fuzheng Injection, China's first pure TCM clear large-volume infusion preparation, and Livzon antiviral granules. The company is currently accelerating the development of over ten new TCM drugs in Categories 1.1 and 3.1.


Through continuous innovation, Livzon has achieved fruitful R&D outcomes, receiving 2 national science and technology awards and 5 provincial/ministerial-level awards. Among them, the projects "R&D and Industrialization of Original Innovative Drug Ilaprazole" and "Research and Application of Triterpenes and Saponins from Chinese Medicine and Natural Products" won the second prize of the National Science and Technology Progress Award. Honors such as "Top 10 in China's Biological Drug R&D Strength, Top 100 in China's Chemical Drug R&D Strength, Landmark Achievement Award of China's Pharmaceutical Science and Technology in the 13th Five-Year Plan, and Top 100 Enterprise in China's Pharmaceutical Industry" are high recognition from various sectors of society for Livzon's pharmaceutical R&D innovation.


Livzon Pharmaceutical will take "patient life quality first" as its mission and "be a leader in pharmaceuticals" as its vision, developing more innovative products to benefit more patients, and contributing to the development of China's national pharmaceutical industry and the cause of human life and health!

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Livzon Group Financing History (1 rounds)

Manage
IPO上市
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market: 主板
  • Deal: 深交所

Livzon Group How Fast Is Hiring Growing? (224 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 5%
  • 2024: Up 22%
  • 2023: Up 27%
  • 2022: Down 56%
Livzon Group Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Livzon Group Campus Recruitment & Advanced Degree Talent Demand
Graduates 1 Interns 1 Master's 35 Doctorate 2
Note: How fast is hiring at Livzon Pharmaceutical Group Inc. growing? Livzon Group2026: 676 openings (up 33%), 2025: 510 openings (up 5%), 2024: 488 openings (up 22%), 2023: 401 openings (up 27%), 2022: 315 openings (down 56%), 2021: 719 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Livzon Group Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Down 65%
  • 2024: Down 35%
  • 2023: Up 93%
  • 2022: Up 72%
Livzon Group Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Livzon Pharmaceutical Group Inc. growing? Livzon GroupMaster's recruitment over the years: 2025: 19 openings (down 65%), 2024: 54 openings (down 35%), 2023: 83 openings (up 93%), 2022: 43 openings (up 72%), 2021: 25 openings. Livzon Group master talent ranking in Zhuhai: #38, Livzon Group master salary mostly around 20-50K.

Livzon Group Doctoral Degree Job Demand Analysis

(More)
+300%
Growth Rate
2026 vs 2025
  • 2025: Down 50%
  • 2024: Down 82%
  • 2023: Up 83%
  • 2022: Up 200%
Livzon Group Doctoral Hiring by Year: 2026 — 3 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at Livzon Pharmaceutical Group Inc. growing? Livzon GroupDoctorate recruitment over the years: 2026: 4 openings (up 300%), 2025: 1 openings (down 50%), 2024: 2 openings (down 82%), 2023: 11 openings (up 83%), 2022: 6 openings (up 200%), 2021: 2 openings.

Livzon Group R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Livzon Pharmaceutical Group Inc.? Based on an analysis of Livzon Group's job postings over the past year, "Medical & Health/Beauty & Healthcare" demand: 26.5%, "Computer/Network/Technology": 10.2%, "Biology/Pharmaceutical/Chemical/Environmental Protection": 9.3%, "Other (R&D and Technical)": 2.8%, "Scientific Research": 1.8%, "Mechanical/Instrumentation": 0.6%. For reference only.

Livzon Group — What Are the Salaries Like? (793 records)

Manage
salary range: 4.5K - 50K, 46.9% of roles pay ¥10-20K
Note: salary statistics are based on 793 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Livzon Pharmaceutical Group Inc.?Livzon Group46.9% of positions earn 10-20K, Fresh graduate salary: ¥4.8K。Zhuhai salary ranking top 20,销售类 average salary ¥17.4K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Livzon Group

(More)
Are salaries high at Livzon Pharmaceutical Group Inc.? We provide: Pharmaceutical Sales Representative, Promotion Specialist, 临床, Sales, Provincial Manager, Marketing, RA, Medical Manager, Key Account Manager, Product Manager, Project Manager, Distribution Representative, Product Manager, Operations, Researcher, Regional Manager, Account Manager, Accountant, Brand, Intern. Click to view detailed salary analysis by job.

Livzon Group — Fortune 500? (More)

Yes, ranked in 中国新经济500强:

  • NO.297 2025中国新经济500强 >
  • NO.228 2024中国新经济500强 >
  • NO.196 2023中国新经济500强 >

Yes, ranked in 中国石油和化工500强:

  • NO.136 2025中国石油和化工500强 >

Job Category

  • 销售类
    51.8% of total 51.8%
  • 医疗卫生/美容保健类
    26.1% of total 26.1%
  • 经营管理类
    20.6% of total 20.6%
  • 市场/公关/媒介类
    11.4% of total 11.4%

Education

  • 本科
    55.4% of total 55.4%
  • 大专
    30.5% of total 30.5%
  • 硕士
    7.9% of total 7.9%
  • 不限
    4.7% of total 4.7%

Experience

  • 1-3年
    36.1% of total 36.1%
  • 3-5年
    29.6% of total 29.6%
  • 不限
    25.4% of total 25.4%
  • 5-10年
    8.6% of total 8.6%
View Detailed Analysis

What does Livzon Pharmaceutical Group Inc. require? Who is Livzon Group hiring? Livzon Group recruitment: 销售类占比最多占51.8%,其次是医疗卫生/美容保健类占26.1%. What education can get in at Livzon Group? 本科占比最多占55.4%,其次是大专占30.5%. High education required at Livzon Group? 硕士占7.9%,博士占0.5%. Work experience required at Livzon Group? 1-3年占比最多占36.1%,其次是3-5年占29.6%. Where are the job locations at Livzon Group? 深圳占比最多占14.1%,其次是珠海占11.5%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 88,790.7171万(元)
Legal Representative: 刘大平
Date Established:
Credit Code: 914404006174883094
Registered Address: 珠海市金湾区创业北路38号总部大楼

Partners & Suppliers

国药控股黑龙江有限公司向丽珠集团采购消化、促性腺激素等药品 Source
合作客户 医药制造-化学药
提供生殖领域数字化决策支持系统。 Source
供应商 医药客户
采购制药设备 Source
供应商 制药企业客户
国药控股分销中心采购并分销丽珠集团药品 Source
合作客户 化学药(处方药)
提供生物药分析检测服务 Source
供应商 医药研发外包服务

People who follow Livzon Group also follow

Livzon Group Competitors (Similar Companies)

“让生命更有价值”
“Caring for Public Health, Creating a Better Life Together”
“Focused on green lighting”
“高端装备制造+环境综合服务商”
试剂 化学制药 医药原料 生物医药
“Top 100 Chinese Pharmaceutical Enterprises”
“Managing health, creating brightness”
“家居塑料用品行业的龙头企业”
“Experts in global pharmaceutical and healthcare”
“Leading enterprise in the field of central nervous system drugs in Chi”
“Home furnishing brand operator”
“供应链管理及综合物流服务商”
“Products for the diagnosis and treatment of allergic diseases”
制冷 压缩机 精密铸造 空调压缩机
“Steroid APIs and preparations. Produce first-class products, committed”

Discover Great Companies, Discover Great Clients

珠海公司名录 珠海“Xiangzhou District”公司名录 珠海“医药”公司名录 珠海“生物医药”公司名录 珠海“生物制药”公司名录 珠海“制药/药业”公司名录 珠海“试剂”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates